AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03428516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto-adjusting CPAP
Description: Auto-adjusting CPAP is a device that applies auto-adjusting continous positive pressure to the airways in order to keep them opened during sleep
Study NCT05933837 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Troponin I
Description: Measurements of plasma Troponin I 6-12 hours and on the first four postoperative days after surgery.
Study NCT03331874 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Reflectance Confocal Microscopy
Description: In-vivo microscope
Study NCT03898245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: apply tDCS
Description: Intensity 2mA, 20minues, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
Study NCT03898245 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Intensity 0mA, 40 seconds, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
Study NCT05169294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Program
Description: Telerehabilitation program: Intervention will be applied by video interview for eight weeks, 3 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on fine motor skills, handwriting skills and activities of daily life of the individuals.
Study NCT05169294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written Home Program
Description: Home program: After the evaluations, the activities towards the determined goals will be communicated to the parents as a home program in written and electronic format. Instructions and key points for the correct implementation of the activities will be presented to the parent, both in writing and verbally; The parent will be able to send questions and receive feedback to the therapists over the phone at any stage of the eight-week home program intervention process. No intervention will be applied to the child through direct video calls.
Study NCT05169294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Home Program
Description: Home program: After the evaluations, the activities towards the determined goals will be communicated to the parents as a home program in written and electronic format. Instructions and key points for the correct implementation of the activities will be presented to the parent, both in writing and verbally; The parent will be able to send questions and receive feedback to the therapists over the phone at any stage of the eight-week home program intervention process. No intervention will be applied to the child through direct video calls.
Study NCT01611259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab and Lenalidomide
Description: Rituximab 375 mg/m² i.v. day 1 Lenalidomide 20 mg p.o. daily for 21 days Cycles should be repeated every 28 days. Restaging should be performed after three cycles. In case of at least stable disease, patients should receive another three courses of therapy. Patients with documented CR after 6 courses will stop therapy/study, while patients with PR or SD will be given another two cycles for a maximum of 8 cycles.
Study NCT04037527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity on a 3+3 escalating dose (100 mg/m² to 300 mg/m²)
Study NCT04037527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity (10 mg/m² to 25 mg/m²).
Study NCT04037527 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation is to be done with standard preop dose of 50 Gy but at lower doses per fraction. Thus 50.4 Gy in 28 FX. Radiation will be given for 5 days (Monday - Friday) every week for approx. 6 weeks.
Study NCT04037527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Upon completing neoadjuvant chemotherapy plus radiation therapy, surgical resection will occur.
Study NCT04037527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Before treatment, blood (about 2 tubes of 10 mls each) to better understand some aspects of participants' immune system before chemotherapy.
Study NCT04363606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of life Depression Physical pain Social provisions Quality of sleep
Study NCT04363606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test
Description: complete blood count and cytokine concentration, TNF-alpha, LDL oxidized, AOPP, SOD, GPX, catalase, albumin, transthyretin, RBP, transferin, α-1 glycoprotein acide, ferritine, selenium, zinc, magnesium
Study NCT04363606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal effort test
Description: The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
Study NCT04363606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: actigraphy
Description: assessment of sleep quality
Study NCT04363606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular evaluation
Description: * The maximum isometric force produced by the knee extensors will be measured on the ergometer~* the intensity of muscular electrical activity recorded by surface electromyography~* Peripheral nerve stimulation~* Transcranial magnetic stimulation~* Magnetic resonance imaging
Study NCT04363606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stool analysis
Description: analyze the composition of the intestinal microbiote. concerns only the patients of Saint Etienne
Study NCT04363606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food diary
Description: 3 days of information to determine nutrient intakes. concerns only the patients of Saint Etienne
Study NCT01158625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change of time of administration
Description: Change of time of administration
Study NCT03844373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: STOCKHOLM
Description: STOCKHOLM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision.
Study NCT03360292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher target range
Description: Intervention is using a higher oxygen saturation target range than in routine practice
Study NCT02362243 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Participants will receive a 45-60 minute, one-time educational session, which will be delivered to delivered by an exercise specialist in a 1-on-1 format while the participant is on-duty at the fire station, in addition to their usual physical fitness routine. Content for the educational session on evidence-based guidelines for exercise, physical fitness, and general physical activity will be derived from the American College of Sports Medicine (ACSM) Position Stand - Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise (Garber, 2011).
Study NCT04313166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu(II)ATSM
Description: cooper-containing synthetic small molecule
Study NCT03521492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum vitamin D , calcium , parathyroid hormone and albumin level
Description: measuring serum level of Vit. D, PTH, Calcium, and Albumin levels
Study NCT02737566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care + Financial Incentives
Description: Tobacco cessation counseling plus pharmacotherapy and financial incentives for quitting.
Study NCT02737566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Tobacco cessation counseling plus pharmacotherapy.
Study NCT00529932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CD133+ infusion
Description: Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).
Study NCT00529932 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: Buffered normal saline will be infused in the coronary artery during an angiography.
Study NCT02209324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Study NCT05705102 — intervention group
Intervention type: OTHER
Intervention: Coronary intervention
Description: Coronary intervention will be done immediately in patients with OMI (even STEMI criteria are negative), instead of waiting for \<24h.
Study NCT04047017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250mg, po, qd
Study NCT04047017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg, q2w
Study NCT02438566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (Oral)
Description: OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
Study NCT02438566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (Intravenous)
Description: IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
Study NCT02100072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG 1440 nm laser
Study NCT01132079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cream treatment
Study NCT01132079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cream treatment
Study NCT03979716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI examination
Study NCT01145079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Description: Zotarolimus-eluting stent
Study NCT01145079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-eluting stent for ACS and DM
Description: Zotarolimus-eluting stent for ACS and DM
Study NCT01145079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent for long lesion
Description: Everolimus-eluting stent for long lesion
Study NCT01145079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent for short lesion
Description: Sirolimus-eluting stent for short lesion
Study NCT05265949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and physical activity intervention
Description: Dietary intervention: Preparation and follow-up of diet program Physical activity intervention: Step count monitoring
Study NCT02442700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin
Description: Treatment A = administration pitavastatin for 12 weeks
Study NCT02442700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Treatment B = administration placebo for 12 weeks
Study NCT01581203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir (ASV)
Study NCT01581203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV)
Study NCT01581203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon alfa 2a (PegIFN)
Study NCT01581203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Study NCT02170753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional manual therapy
Description: The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy.
Study NCT02170753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard physical therapy
Description: The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
Study NCT02170753 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
Study NCT00439140 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A injection into the detrusor.
Study NCT00439140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A injection into the detrusor.
Study NCT00439140 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline (Placebo)
Description: Placebo (Normal Saline) injection into the detrusor.
Study NCT04595838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chemo Mouthpiece
Description: Frozen tube that fills the oral cavity used during and after chemotherapy to ease and prevent symptoms of oral mucositis
Study NCT04595838 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care only
Description: Standard Oral care for Chemotherapy
Study NCT02012946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: patient receiving levosimendan
Study NCT02012946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: patient receiving dobutamine
Study NCT03553745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gentle Yoga Intervention
Description: 10-week exercise program structured around gentle yoga practice.
Study NCT03553745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rigorous Yoga Intervention
Description: 10-week exercise program structured around rigorous yoga practice.
Study NCT03553745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise Intervention
Description: 10-week exercise program structured around cardiovascular exercise.
Study NCT00159523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Study NCT00159523 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00834301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Multivitamin
Description: Oral Multivitamin
Study NCT01798446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.
Study NCT03544983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web + Streamlined Telephone Genetic Information
Description: Tailored and interactive web-based education designed to incorporate all aspects of standard genetic counseling followed by a streamlined genetic counseling session with a board-certified genetic counselor.
Study NCT03835442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: baclofen 10mg tid for 4 weeks
Study NCT03835442 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo tid for 4 weeks
Study NCT04638608 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EMBRACE (relatives)
Description: Online support program for both relatives
Study NCT04638608 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EMBRACE (Health care providers)
Description: Online support program for health care providers
Study NCT00053430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Tablet taken orally daily
Study NCT00053430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thalidomide placebo
Description: Placebo tablet taken orally daily
Study NCT02201797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DCE MRI
Study NCT02803710 — intervention group
Intervention type: OTHER
Intervention: Microbiological study
Study NCT00503035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg by mouth twice daily x 6 months
Study NCT00503035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy Biopsy
Description: Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure
Study NCT03070327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRt/BCMA-41BBz CAR T cell
Description: Modified T cell infusions will be administered 2-7 days following the completion of conditioning chemotherapy.There are 3 planned dose levels for this study: 1x10\^6, 3x10\^6, and 1x10\^7 EGFRt/BCMA-41BBz CAR T cells/kg, and a dose -1 level at 3x10\^5 EGFRt/BCMA-41BBz CAR T cells/kg, if needed; each dose cohort will consist of 3-6 patients.
Study NCT03070327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 3000 mg/m2 IV once on day -7 to -2 or low intensity cy/flu (cyclophosphamide 300 mg/m2/day x 3 + fludarabine 30 mg/m2/day x 3) with the last day occurring on day -7 to -2 are the default options for is the default conditioning chemotherapy.
Study NCT03070327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide.
Description: A cohort of patients will be treated with CAR T cell therapy and concomitant Lenalidomide. 10mg PO 21/28 days will be started no less then 1 week prior to clinical apheresis.
Study NCT03138135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOME Study intervention
Description: Access to home HIV test kits, home STI self-collection kits, the HOME Study website, and the SexPro HIV risk assessment tool.
Study NCT03138135 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Counseling about the importance of quarterly HIV/STI testing and a PrEP information pamphlet.
Study NCT02790619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS via Chattanooga Ionto Iontophoresis System-Phoresor
Description: Small electrical current delivered non-invasively to the scalp. 1mA electrical current to Meditation and Active Stimulation 1 condition. 2mA to Meditation and Active 2 Stimulation condition.
Study NCT02790619 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor
Description: Blinds participants to meditation condition by applying 30 seconds of real stimulation and then turning the device off.
Study NCT02801838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: If the physician in charge of the patients judges it necessary, after the optimization of the ventilators settings, if the patient remains uncomfortable, a second therapeutic intervention using a maximum of 10mg morphine titration may be performed. After this second therapeutic intervention, a third non-verbal measure of respiratory discomfort will be performed with the IC-RDOS. Concomitantly, EEG and EMG will be again recorded over a of 15-minutes period.
Study NCT04400175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valved ergonomic teat
Description: Administration of milk with a feeding system with a valved ergonomic teat in late preterm newborns.
Study NCT04400175 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard silicon teat
Description: Administration of milk with a feeding system with a standard silicon teat
Study NCT03427788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065
Description: Doses from 2.25-700 mg once daily in an escalating manner as liquid service formulation (LSF) or tablets
Study NCT03427788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, once daily in an escalating manner as LSF or tablets
Study NCT00514501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodofiltic acid I 123
Study NCT02651974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
Study NCT02651974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cost condition
Description: Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
Study NCT02651974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cost/Future condition
Description: Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.